SCHEMBL29567109

SCHEMBL29567109

Cc1cccc(S(=O)(=O)Nc2nc(Oc3ccccc3F)cc(-c3ccccc3C(C)C)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.42
▸ LMNA P02545 2/20 0.40
▸ HTT P42858 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ NLRP3 Q96P20 1/20 0.39
▸ TSHR P16473 3/20 0.39
▸ KAT6A Q92794 2/20 0.38
▸ BRD4 O60885 2/20 0.38
▸ SCN9A Q15858 3/20 0.37
▸ HTR1A P08908 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ SLC40A1 Q9NP59 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24310800 1.00 TDP1 (0.42) TDP1LMNAHTTSMN1; SMN2MEN1
SCHEMBL29567008 0.92 TDP1 (0.45) TDP1LMNAHTTSMN1; SMN2KDM4E
SCHEMBL24309354 0.92 TDP1 (0.45) TDP1LMNAHTTSMN1; SMN2KDM4E
SCHEMBL26812870 0.91 TDP1 (0.47) TDP1LMNAHTTSMN1; SMN2MEN1
SCHEMBL29566464 0.90 KDM1A (0.45) TDP1LMNAHTTMEN1KMT2A
SCHEMBL24310091 0.90 TDP1 (0.41) TDP1LMNAHTTSMN1; SMN2MEN1
SCHEMBL29567206 0.90 TDP1 (0.41) TDP1LMNAHTTSMN1; SMN2MEN1
SCHEMBL26812774 0.90 KDM1A (0.45) TDP1LMNAHTTMEN1KMT2A
SCHEMBL26806777 0.90 TDP1 (0.40) TDP1LMNAHTTSMN1; SMN2KMT2A
SCHEMBL24310082 0.89 ALPL (0.42) TDP1LMNAHTTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4225748-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-08-16 — — EP disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 — — WO disclosed
Send feedback